(MENAFN- GlobeNewsWire - Nasdaq) LOS ANGELES, Oct. 03, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Cytokinetics, Inc., (“Cytokinetics” or the "Company") (NASDAQ: CYTK) investors of a class action on behalf of investors that bought securities between December 27, 2023 and May 6, 2025, inclusive (the“Class Period”). Cytokinetics investors have until November 17, 2025 to file a lead plaintiff motion.

Investors are encouraged to contact attorney Lesley F. Portnoy , by phone 844-767-8529 or email : ... , to discuss their legal rights, or join the case via . The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing claims to recover their losses.

According to the complaint, during the class period, defendants made materially false and misleading statements regarding the timeline for the New Drug Application ("NDA") submission and approval process for aficamten. Specifically, Defendants represented that the Company expected approval from the U.S. Food and Drug Administration for its NDA for aficamten in the second half of 2025, based on a September 26, 2025 PDUFA date, and failed to disclose material risks related to the Company's failure to submit a Risk Evaluation and Mitigation Strategy that could delay the regulatory process. Shareholders suffered financial losses when the truth was revealed.

The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing. The Firm's founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA, NY and TX Bar
...
310-692-8883

Attorney Advertising

MENAFN03102025004107003653ID1110147677